.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,260,291

« Back to Dashboard

Summary for Patent: 5,260,291

Title: Tetrazine derivatives
Abstract:[ 3H]-Imidazo[ 5,1-d] -1,2,3,5-tetrazin-4-one derivatives of the formula: ##STR1## wherein R.sup.1 represents hydrogen, or an alkyl, alkenyl or alkynyl group containing up to 6 carbon atoms, each such group being unsubstituted or substituted by from one to three substituents selected from halogen atoms, alkoxy, alkylthio, alkylsulphinyl and alkylsulphonyl groups containing up to 4 carbon atoms, and optionally substituted phenyl groups, or R.sup.1 represents a cycloalkyl group containing from 3 to 8 carbon atoms, and R.sup.2 represents a carbamoyl group optionally N-substituted by one or two groups selected ftom alkyl and alkenyl groups containing up to 4 carbon atoms, and cycloalkyl groups containing 3 to 8 carbon atoms, are new therapeutically useful compounds possessing antineoplastic and immunomodulatory activity.
Inventor(s): Lunt; Edward (Norfolk, GB2), Stevens; Malcolm F. G. (Birmingham, GB2), Stone; Robert (Montrose, AU), Wooldridge; Kenneth R. H. (Lincolnshire, GB2), Newlands; Edward S. (London, GB2)
Assignee: Cancer Research Campaign Technology Limited (London, GB2)
Application Number:07/781,020
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 5,260,291

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8125791Aug 24, 1981

International Patent Family for Patent: 5,260,291

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria380256<disabled in preview>
AustriaA319182<disabled in preview>
Australia571430<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc